Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience

1. Diop S, Haffar A, Mahlangu J, et al. Improving access to hemophilia care in sub-Saharan Africa by capacity building. Blood Adv 2019; 3(Suppl 1): 1–4. doi: 10.1182/bloodadvances.2019GS121537. DiopS HaffarA MahlanguJ Improving access to hemophilia care in sub-Saharan Africa by capacity building Blood Adv 2019 3 Suppl 1 1 4 10.1182/bloodadvances.2019GS121537 Open DOISearch in Google Scholar

2. Ndoumba-Mintya A, Diallo YL, Tayou TC, Mbanya DN. Optimizing haemophilia care in resource-limited countries: current challenges and future prospects. J Blood Med 2023; 14: 141–6. doi: 10.2147/JBM.S291536. Ndoumba-MintyaA DialloYL TayouTC MbanyaDN Optimizing haemophilia care in resource-limited countries: current challenges and future prospects J Blood Med 2023 14 141 6 10.2147/JBM.S291536 Open DOISearch in Google Scholar

3. Pierce GF, Adediran M, Diop S, Dunn AL, El Ekiaby M, et al. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol 2022; 9(9): e689–e97. doi: 10.1016/S2352-3026(22)00209-5. PierceGF AdediranM DiopS DunnAL El EkiabyM Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years Lancet Haematol 2022 9 9 e689 e97 10.1016/S2352-3026(22)00209-5 Open DOISearch in Google Scholar

4. Blair HA. Emicizumab: A review in haemophilia A. Drugs 2019; 79(15): 1697–707. doi: 10.1007/s40265-019-01200-2. BlairHA Emicizumab: A review in haemophilia A Drugs 2019 79 15 1697 707 10.1007/s40265-019-01200-2 Open DOISearch in Google Scholar

5. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377(9): 809–18. doi: 10.1056/NEJMoa1703068. OldenburgJ MahlanguJN KimB Emicizumab prophylaxis in hemophilia A with inhibitors N Engl J Med 2017 377 9 809 18 10.1056/NEJMoa1703068 Open DOISearch in Google Scholar

6. Callaghan MU, Negrier C, Paz-Priel I, Chang T, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1–4 studies. Blood 2021; 137(16): 2231–42. doi: 10.1182/blood.2020009217. CallaghanMU NegrierC Paz-PrielI ChangT Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1–4 studies Blood 2021 137 16 2231 42 10.1182/blood.2020009217 Open DOISearch in Google Scholar

7. Warren BB, Chan A, Manco-Johnson M, et al. Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report. Res Pract Thromb Haemost 2021; 5(5): e12571. doi: 10.1002/rth2.12571. WarrenBB ChanA Manco-JohnsonM Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report Res Pract Thromb Haemost 2021 5 5 e12571 10.1002/rth2.12571 Open DOISearch in Google Scholar

8. Arcudi S, Gualtierotti R, Marino S, et al. Real-world data on emicizumab prophylaxis in the Milan cohort. Haemophilia 2022; 28(5): e141–e144. doi: 10.1111/hae.14630. ArcudiS GualtierottiR MarinoS Real-world data on emicizumab prophylaxis in the Milan cohort Haemophilia 2022 28 5 e141 e144 10.1111/hae.14630 Open DOISearch in Google Scholar

9. Levy-Mendelovich S, Brutman-Barazani T, Budnik I, et al. Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab. J Clin Med 2021; 10(19): 4303. doi: 10.3390/jcm10194303. Levy-MendelovichS Brutman-BarazaniT BudnikI Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab J Clin Med 2021 10 19 4303 10.3390/jcm10194303 Open DOISearch in Google Scholar

10. Liu G, Huang K, Li G, et al. Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China. Front Pediatr 2022; 10: 992267. doi: 10.3389/fped.2022.992267. LiuG HuangK LiG Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China Front Pediatr 2022 10 992267 10.3389/fped.2022.992267 Open DOISearch in Google Scholar

11. Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia 2022; 28 Suppl 4(Suppl 4): 103–10. doi: 10.1111/hae.14524. MahlanguJ IorioA KenetG Emicizumab state-of-the-art update Haemophilia 2022 28 Suppl 4 Suppl 4 103 10 10.1111/hae.14524 Open DOISearch in Google Scholar

12. Lambert C, Meité N'D, Kouassi GK, et al. Nonreplacement therapy for hemophilia in low-income countries: experience from a prospective study in Ivory Coast. Res Pract Thromb Haemost 2022; 7(1): 100033. doi: 10.1016/j.rpth.2022.100033. LambertC MeitéN'D KouassiGK Nonreplacement therapy for hemophilia in low-income countries: experience from a prospective study in Ivory Coast Res Pract Thromb Haemost 2022 7 1 100033 10.1016/j.rpth.2022.100033 Open DOISearch in Google Scholar

13. Barg AA, Livnat T, Budnik I, et al. Emicizumab treatment and monitoring in a paediatric cohort: real-world data. Br J Haematol 2020; 19(2): 282–90. doi: 10.1111/bjh.16964. BargAA LivnatT BudnikI Emicizumab treatment and monitoring in a paediatric cohort: real-world data Br J Haematol 2020 19 2 282 90 10.1111/bjh.16964 Open DOISearch in Google Scholar

14. Li A, Goodfriend C, Sokol J, Kruse-Jarres R. Patterns and predictors of emicizumab adherence in people with hemophilia. Blood 2019; 134(Supplement 1): 128083. doi: 10.1182/blood-2019-128083. LiA GoodfriendC SokolJ Kruse-JarresR Patterns and predictors of emicizumab adherence in people with hemophilia Blood 2019 134 Supplement 1 128083 10.1182/blood-2019-128083 Open DOISearch in Google Scholar

15. Schrijvers LH, Beijlevelt-van der Zande M, Peters M, Lock J, et al. Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study. Br J Haematol 2016; 174(3): 454–60. doi: 10.1111/bjh.14072. SchrijversLH Beijlevelt-van der ZandeM PetersM LockJ Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study Br J Haematol 2016 174 3 454 60 10.1111/bjh.14072 Open DOISearch in Google Scholar

16. Okolo A, Shapiro A, Janson I, et al. Psychometrics and applications of a novel self-report measure of emicizumab adherence: VERITASNexGen. Haemophilia 2023; 29(5): 1299–1305. doi: 10.1111/hae.14851. OkoloA ShapiroA JansonI Psychometrics and applications of a novel self-report measure of emicizumab adherence: VERITASNexGen Haemophilia 2023 29 5 1299 1305 10.1111/hae.14851 Open DOISearch in Google Scholar